Harwell’s clients have included former San Francisco 49ers owner Eddie DeBartolo in numerous matters, as well as Ford, ...

Pfizer is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years.Shares are down 19% over the past ...

The HER2-targeted antibody-drug conjugate that Pfizer gained from its Seagen buyout has delivered positive results in a pivotal study among Chinese patients with newly diagnosed bladder cancer ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses. During a recent episode of Mad Money, which aired on Monday ...

Income investors have liked Pfizer (NYSE: PFE) for years. However, the big drugmaker's exceptionally juicy dividend these days has made its stock even more attractive. But when a dividend yield ...

The temporal relationship between the development of symptoms about three days after gabapentin discontinuation and the absence of any improvements during the administration of benzodiazepines for ...

Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...

--Down 18.97% from 52 weeks ago (May 13, 2024), when it closed at $28.44 --Down 26.58% from its 52-week closing high of $31.39 on July 30, 2024 --Up 6.74% from its 52-week closing low of $21.59 on ...

Pfizer could soon launch a multi-billion dollar bid for immunotherapy rivals Bristol-Myers Squibb. But moves into new fields of innovation and digital tech – such as Roche’s buyout of Flatiron ...

NEW YORK, April 29, 2025--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1). NEW YORK, April 26, 2025--Pfizer Inc ...

Menopause is notorious for causing symptoms like hot flashes, night sweats, and mood swings. Insomnia is another challenge women face during this transition. Between 40 and 60 percent of ...

Lexicon Pharmaceuticals reported its Q1 2025 earnings, revealing a smaller-than-expected loss per share and a significant drop in revenue compared to forecasts. The company posted an EPS of -$0.07 ...